Gladstone brings together investigators and partners who recognize that potential early on—and bring the expertise, resources, and perspective to help move it forward.
Whether you’re an industry partner looking for promising science, an investor or entrepreneur exploring new opportunities, or a research institution seeking collaboration, Gladstone offers flexible ways to engage with discoveries at the forefront of human health.
GABAeron uses engineered stem cell lines, genetic data and small-molecule drugs to develop therapeutics that may preserve or restore brain function in Alzheimer’s disease.
Tenaya Therapeutics addresses heart failure by targeting the cellular pathologies present in diseased cardiac muscle and leveraging cutting-edge research in cardiac development and regeneration.
Therini is a vascular biology company focused initially on developing novel therapies based on a deep understanding of fibrin and its role in driving pathological inflammatory processes—a new biological target.
Finding the right partner can help accelerate scientific discovery and impact.
Through sponsored research, companies can work directly with Gladstone investigators and gain access to distinct scientific expertise, expansive research capabilities, and emerging discoveries.
Gladstone works with its investigators and industry partners to develop a research plan, scope, budget, and milestones tailored to advance scientific knowledge of mutual interest.
Where appropriate, sponsored research can also create a pathway toward commercialization, including an option to negotiate an exclusive license for intellectual property arising from the collaboration.
For companies and investigators alike, sponsored research creates an opportunity to pursue promising ideas together and explore where the science can lead.
If you’d like to explore opportunities to partner with Gladstone, contact the Industry and Ventures Team.
Some of tomorrow’s therapeutics, technologies, research tools, and platforms are taking shape at Gladstone today.
Our investigators work on some of the most challenging problems in human health, generating discoveries that can open new scientific and commercial possibilities.
We work with startups, established companies, investors, and research institutions to identify promising technologies and create pathways for their development. Our licensing approach is flexible and responsive to the technology, its stage of development, and the needs of the partner.
Explore Gladstone’s intellectual property portfolio or talk with us about what you’re looking for. Some opportunities are ready to license today; others are still emerging.
Sometimes a discovery needs more than a license. It needs a company built around its potential.
When Gladstone research reveals a promising therapeutic, platform, or commercial opportunity, we work with our investigators, founders, investors, and other partners to determine the path that gives the science its best opportunity to advance.
For founders, investors, and strategic partners, Gladstone offers access to high-quality science, experienced investigators, and emerging opportunities at the point where scientific discovery begins to reveal commercial potential.
Mala Sahai, JD
Senior Director, Intellectual Property and Legal Affairs
Eve Bland
Patent Agent
Girard Courteau
Patent Counsel
Audrey Le
Administrative Program Manager
Alecia Muth, MS
Strategic Partnership and Ventures Manager
Irene Shin
Intellectual Property Counsel
Veronica Viray
Associate Director, Intellectual Property and Legal Affairs
Raised in private and public financing capital from spinouts
Of investigators are company founders
Startups created based on Gladstone technologies since 2007
Of investigators collaborate with industry
A new discovery reveals how a SARS-CoV-2 protein reprograms immune cells to accelerate viral spread—and points to a new strategy for therapeutic intervention.
The fellowship provides three years of funding for graduate students pursuing groundbreaking immunology research.
Takahashi is recognized for his pioneering work translating iPS cell technology into a clinically approved therapy for Parkinson’s disease.
An unprecedented map of 22 million immune cells provides the functional rulebook for virtual biology and next-generation immunotherapies.
Our people are our most important asset. We offer a wide array of career opportunities both in our administrative offices and in our labs.
Open PositionsDiscoveries don’t stay in our labs. Gladstone facilitates spinout companies to advance promising therapies, shortening the path between scientific discovery and helping real patients.
Learn MoreYour gift to Gladstone will allow our researchers to pursue high-quality science, focus on disease, and train the next generation of scientific thought leaders.
Donate Now
